Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of superoxide dismutase activity. [GOC:TermGenie]
Positive regulation of superoxide dismutase activity is a complex biological process involving various cellular mechanisms that enhance the activity of superoxide dismutase (SOD), a key enzyme in the defense against oxidative stress. SOD catalyzes the dismutation of superoxide radicals (O2-) into hydrogen peroxide (H2O2) and oxygen (O2), thus preventing the formation of highly reactive hydroxyl radicals.
**Molecular Mechanisms:**
1. **Transcriptional Regulation:**
- Transcription factors like Nrf2 (nuclear factor erythroid 2-related factor 2) and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) can bind to specific DNA sequences in the promoter region of SOD genes, stimulating their transcription and enhancing SOD expression.
- These transcription factors are activated by various cellular signals, including oxidative stress, inflammation, and exposure to environmental toxins.
2. **Post-translational Modifications:**
- SOD activity can be regulated by post-translational modifications, such as phosphorylation and acetylation.
- These modifications can alter the enzyme's conformation and activity. For instance, phosphorylation of SOD1 (a major form of SOD in the cytoplasm) by specific kinases can enhance its enzymatic activity.
3. **Protein-Protein Interactions:**
- SOD can interact with other proteins to form complexes that modulate its activity.
- For example, SOD1 interacts with chaperone proteins like Hsp70, which assist in its folding and stability.
4. **Metal Ions:**
- SOD requires metal ions, such as copper, zinc, or manganese, for its catalytic activity.
- These ions are incorporated into the enzyme during its biosynthesis and are essential for its proper function.
**Cellular Response to Oxidative Stress:**
- Oxidative stress, caused by an imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense system, triggers a cellular response to enhance SOD activity.
- This response involves signaling pathways that activate transcription factors, regulate gene expression, and modulate post-translational modifications, ultimately leading to increased SOD activity and protection against oxidative damage.
**Consequences of Impaired Regulation:**
- Deficiencies or dysregulation in positive regulation of SOD activity can lead to increased oxidative stress, contributing to various diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, and aging.
**Therapeutic Potential:**
- Understanding the intricate mechanisms involved in positive regulation of SOD activity has opened avenues for developing therapeutic strategies aimed at boosting SOD levels and activity, potentially mitigating oxidative stress-related pathologies.'
"
Protein | Definition | Taxonomy |
---|---|---|
NAD-dependent protein deacetylase sirtuin-3, mitochondrial | An NAD-dependent protein deacetylase sirtuin-3, mitochondrial that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NTG7] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
niacinamide | nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group. | pyridine alkaloid; pyridinecarboxamide; vitamin B3 | anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor |
amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
ro 31-8220 | Ro 31-8220: a protein kinase C inhibitor | imidothiocarbamic ester; indoles; maleimides | EC 2.7.11.13 (protein kinase C) inhibitor |
honokiol | biphenyls | ||
4-methylnicotinamide | 4-methylnicotinamide: structure given in first source | ||
resveratrol | trans-resveratrol : A resveratrol in which the double bond has E configuration. | resveratrol | antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger |
3-(1-azepanylsulfonyl)-n-(3-bromphenyl)benzamide | 3-(1-azepanylsulfonyl)-N-(3-bromphenyl)benzamide: a sirtuin 2 inhibitor; structure in first source | ||
cambinol | cambinol: inhibitor of human silent information regulator 2 enzymes; structure in first source | ||
(4-chlorophenyl)-[4-(8-nitro-5-quinolinyl)-1-piperazinyl]methanone | N-arylpiperazine | ||
ex 527 | 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source | carbazoles; monocarboxylic acid amide; organochlorine compound | |
panobinostat | panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma. Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA. | cinnamamides; hydroxamic acid; methylindole; secondary amino compound | angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor |
quisinostat | indoles | ||
srt1460 | SRT1460: small molecule activator of SIRT1 as therapeutics for the treatment of type 2 diabetes; structure in first source | ||
srt1720 | |||
srt2183 | SRT2183: small molecule activator of SIRT1 as therapeutics for the treatment of type 2 diabetes; structure in first source | ||
tenovin-6 | tenovin-6 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(dimethylamino)pentanoic acid with the aromatic amino group of N-[(4-aminophenyl)carbamothioyl]-4-tert-butylbenzamide. | monocarboxylic acid amide; tertiary amino compound; thioureas | antineoplastic agent; p53 activator; Sir2 inhibitor |
n-(3-((2-hydroxynaphthalen-1-ylmethylene)amino)phenyl)-2-phenylpropionamide |